Injecting drug use increases the risk of death in HIV patients on antiretroviral therapy in Vietnam

• Published in: AIDS care Vol. 36; no. 5; p. 631
• Main Authors: Araujo Chaveron, Lucia, Pham, Tram Thi Phuong, Nguyen, Binh Thanh, Tran, Tram Hong, Le, Nhung Thi Hong, Pham, Thang Hong, Ngo, Khanh Phuong, Tong, Ha Thi, Phan, Huong Thi Thu, Ait-Ahmed, Mohand, Nguyen, Tuan Anh, Taieb, Fabien, Madec, Yoann
• Format: Journal Article
• Language: English
• Published: England 03.05.2024
• Subjects: Adult; Female; HIV; HIV Infections - epidemiology; Humans; Incidence; Lost to Follow-Up; Male; Prospective Studies; Substance Abuse, Intravenous - complications; Substance Abuse, Intravenous - epidemiology; Vietnam - epidemiology; Vietnam; lost to follow-up; mortality; intravenous substance abuse; HIV; Asia; antiretroviral therapy
• ISSN: 1360-0451
• DOI: 10.1080/09540121.2023.2224549

The Human Immunodeficiency Virus (HIV) epidemic remains a major public health issue worldwide. In Vietnam, the HIV epidemic is essentially driven by people who inject drugs (PWID). This study aims to compare mortality and loss to follow-up (LTFU) between PWID and other patients. From June 2017 to April 2018, HIV-infected adults were enrolled in a prospective cohort from time of ART initiation in six provinces of North Vietnam. The end date was July 2020. Mortality and LTFU were described using competing-risk survival models. Factors associated with mortality and with LTFU were identified using Cox models with a competing-risk approach. Of the 578 participants, 261 (45.2%) were PWID and almost exclusively male. 49 patients died, corresponding to a mortality rate (95% confidence interval (CI)) of 3.7 (2.8-4.9) per 100 person-months, and 79 were lost to follow-up, corresponding to a rate (95% CI) of 6.0 (4.8-7.4) per 100 person-months. PWID were at higher risk of death but not of LTFU. Overall, LTFU was high in both groups. Latecomers to clinical visits were more at risk of both death and LTFU. Therefore, this should be a warning to clinical teams and preventive actions taken in these patients. ClinicalTrials.gov identifier: NCT03249493..